Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
$9.29
-$0.20(-4.12%)
At close: 4:00 PM EST
$9.29
-$0.20(-4.12%)
Day’s Range― - ―
52-Week Range$3.81 - $9.94
Previous CloseN/A
Volume240.10K
Average Volume (3M)3.46M
Market Cap
$549.11M
Enterprise Value$448.51M
Total Cash (Recent Filing)$263.85M
Total Debt (Recent Filing)$12.62M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
May 06, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding59,108,030
10 Day Avg. Volume2,244,326
30 Day Avg. Volume3,463,371
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.59
Price to Sales (P/S)2.41
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.08
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda-3.51
Forecast
1Y Price Target
$15.50Price Target Upside66.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.26
Revenue Forecast (FY)$257.43M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyA single dose of imsidolimab produced substantially higher rates of rapid disease clearance versus placebo with durable benefit and a favorable safety profile, supporting its potential as a differentiated treatment for generalized pustular psoriasis.
Commercial Opportunity For New ProductApproval of tradipitant for motion sickness would introduce the first new pharmacologic option in many years and could expand use beyond sea travel, offering a meaningful new revenue stream.
Regulatory Review PathwayA federal appeals court remanded the tasimelteon application and the FDA granted a formal evidentiary hearing, creating a clear pathway for re-review that could enable approval for a jet lag indication.
Bears Say
Approval Uncertainty For Jet LagThe FDA determined that the clinical models did not sufficiently mimic actual jet travel and found the tasimelteon data insufficient for approval, raising the likelihood of additional studies or extended regulatory review.
European Regulatory SetbackThe European regulator recommended refusal of iloperidone marketing authorization in Europe, creating uncertainty for potential sales and requiring a re-examination process to restore access.
Financial Performance PressureRecent quarterly results missed expectations and showed a wider loss driven by higher research and selling expenses, indicating near-term pressure on profitability and cash flow.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.81 and its highest was $9.94 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $549.11M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is May 06, 2026 which is in 53 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Feb 11, 2026. The company reported -$2.39 earnings per share for the quarter, missing the consensus estimate of -$0.975 by -$1.415.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.69.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 59,108,030 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$2.39 in its last earnings report, missing expectations of -$0.975. Following the earnings report the stock price went down -17.631%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (66.85% Upside)
$15.50 (66.85% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 23.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 14.0%
Last 30 Days ▲ 14.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.54%
12-Months-Change
Fundamentals
Return on Equity
-49.24%
Trailing 12-Months
Asset Growth
-25.49%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
VNDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced mix of strong commercial momentum and regulatory progress alongside material near-term financial and execution challenges. Highlights include robust Fanapt prescription growth, a meaningful FY revenue increase, FDA approval of Nereus and multiple late-stage pipeline advances with revenue guidance implying continued growth. Lowlights include a large FY net loss driven in part by a one-time $113.7M valuation allowance, substantially higher operating expenses, declining HETLIOZ sales amid generic competition, reduced cash balances with expected higher cash burn in 2026, and some clinical enrollment and inventory timing risks. Given the sizable commercial and regulatory positives tempered by significant near-term financial and execution risks, the overall tone is cautiously balanced.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(66.85% Upside)
Technical Analysis
Ownership Overview
7.36% Insiders
15.22% Mutual Funds
6.14% Other Institutional Investors
58.64% Public Companies and
Individual Investors